Renata Colombo Bonadio, MD
@renata_bonadio
Followers
1K
Following
595
Statuses
189
Medical Oncologist - Instituto do Câncer do Estado de São Paulo @ICESP_ - Oncologia D’Or #BreastCancer #GynecologicCancer
Joined January 2019
RT @LisRavani: Proud to share our work in @JCOOP_ASCO ! 📢Our meta-analysis of 4,899 patients explored the efficacy of different treatment…
0
2
0
RT @antgiorda: One of the most brilliant discussant at #SABCS24 @BianchiniGP Don’t miss the opportunity to treat ER low (1-9%) with chemo…
0
24
0
0
0
0
#SABCS24 📍Dose-dense AC associated with higher RCB 0-1 rate compared to q3w AC during neoadjuvant CT+pembro for TNBC 📍Neo-Real study @LauraTestaMD @DrRBarroso @DGagliato @assad_daniele
@GBECAMConnect @OncoAlert
0
41
103
RT @OncoAlert: The #OncoAlert5k Homecoming in San Antonio Thank you all for a Fantastic Year🚨 See y'all at #OncoAlert5k #ASCO25
@maur_jmp…
0
9
0
RT @GBECAMConnect: 🇧🇷✨👀Don’t miss out today! Renata Bonadio and co-authors: P2-11-14: Treatment Patterns and Safety of Adjuvant Therapy Aft…
0
4
0
Important data presented by @matteolambe at #SABCS2024 @OncoAlert 📍Among young BRCA carriers with a history of breast cancer, risk reducing mastectomy improves overall survival. 📍Benefit seem especially in BRCA1 carriers 📍Benefit regardless of risk reducing oophorectomy
0
9
28
0
0
0
RT @DrRBarroso: We are pleased with the publication of the Neo-Real study (GBECAM-0123), which evaluated RWD from 10 Brazilian centers, co…
0
46
0
RT @CMHidalgoFilho: Excited to share our publication in JCO Global Oncology! We analyzed the patterns of unplanned hospitalization among c…
0
3
0
@paulohoff10 @Icesp_ @dor_oncologia #ASCO24 📌ctDNA as a predictor of recurrence in cervical and anal cancer after treatment with chemoradiation.
O trabalho tem como autor sênior o oncologista Paulo Hoff, com resultados que apoiam o valor preditivo desse biomarcador nessa população de pacientes. Leia mais:
0
1
11
RT @PortalOnconews: O trabalho tem como autora sênior a oncologista Renata Bonadio (foto), do Instituto D’Or de Pesquisa e Ensino (IDOR), e…
0
1
0
RT @AndradeMO_MD: Our review article regarding breast cancer visceral crisis is available online! @renata_bonadio @LauraTe96206949 Visce…
0
2
0
RT @ASTRO_org: In this new #RedJournal article, @petry_v @renata_bonadio et. al discuss the frequency of radiotherapy-induced malignancies…
0
6
0
@RenoHemonc @OncoAlert @DrRBarroso @LauraTestaMD @bruna_zucchetti @DGagliato @MayanaNavarro Every 3 weeks! Pts had to come two days more for the infusions of pembrolizumab that were applied in different days from AC.
0
0
1
@z_veitch @OncoAlert @DrRBarroso @LauraTestaMD @bruna_zucchetti @DGagliato @MayanaNavarro Thank you! All patients received weekly paclitaxel and the large majority received weekly carboplatin. The dd vs q3w was for the AC portion. Around 60% of the physicians used ddAC.
2
0
0
#SABCS23 - HER2CLIMB-02: T-DM1+Tucatinib for mHER2+BC after trastuzumab+taxane + of tucatinib: PFS benefit (9.5 vs 7.4 m), including in the brain metastases (BM) group. How does this fit in with the now standard 2nd line T-Dxd? What is the preferred 2nd line for pts with BM?
0
0
1